ArticleFrontiers in immunology2026
Development and validation of a pseudotyped virus neutralization assay for quantification of anti-Lassa virus neutralizing antibodies.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lassa virus is endemic in many West African countries and has significant epidemic/pandemic potential. The Coalition for Epidemic Preparedness Innovations (CEPI) Centralized Laboratory Network (CLN) is developing validated, harmonized methods to support and accelerate vaccine development in the event of an outbreak. We present here the development and validation of an assay to quantify anti-Lassa virus neutralizing antibodies. As the method uses a pseudotyped virus (PV) instead of authentic Lassa virus-a pathogen listed as hazard group 4-it can be performed at a lower containment level, making it widely accessible especially in those regions where Lassa fever is circulating. Methods: A recombinant vesicular stomatitis virus (rVSV)-based pseudotyped virus neutralization assay (PVNA) was developed. A working standard was prepared and calibrated against the International Standard (IS) for Lassa virus neutralizing antibodies, enabling results to be expressed in International Units. The method was validated according to the International Council for Harmonisation (ICH) Q2(R2) guidelines. Results: The rVSV-based PVNA was successfully developed and validated. The analytical range of the assay was established as 10-100 IU/mL, and seropositive samples from a Lassa vaccine clinical trial fell within this range. Results from the PVNA showed direct correlation with results obtained from authentic virus neutralization methods. The method was, therefore, concluded to be fit-for-purpose. Conclusion: We have successfully developed and validated a PVNA for the quantification of neutralizing antibodies against Lassa virus. We have also provided a practical example of how to calibrate a serological method to the WHO International Standard to achieve greater harmonization and comparability between studies. The method is now being transferred to partner laboratories within the CLN to enable harmonized testing of clinical trial samples and support the development and evaluation of Lassa vaccine candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.